# US 2019/0170776 A1 · Methods and Kits for the Derivatization of a Biogenic Amine

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0170776 A1
- Document ID: US20190170776A1
- Status: Published application
- Kind: A1
- Application number: 16/304,376
- Filed: 2017-05-24
- Published: 2019-06-06
- Earliest claimed: 2016-05-26
- Assignees: Rijksuniversiteit Groningen; Academisch Ziekenhuis Groningen
- Applicants: Rijksuniversiteit Groningen; Academisch Ziekenhuis Groningen
- Inventors: Ido Peter KEMA; Claude Pascal VAN DER LEY; Hermannus Johannes Roelof VAN FAASSEN
- Web page: https://patentgrep.com/patent/US20190170776A1

## CPC

- G01N 33/9406: {Neurotransmitters}
- G01N 33/6812: {Assays for specific amino acids}
- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 33/94: involving narcotics {or drugs or pharmaceuticals, neurotransmitters or associated receptors}
- G01N 2560/00: Chemical aspects of mass spectrometric analysis of biological material
- Y10T 436/173845: Amine and quaternary ammonium
- Y10T 436/24: Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- Y10T: TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION

## Abstract

The invention relates to analytical chemistry, in particular to means and methods for the quantitative determination of derivatized biogenic amines, precursors or metabolites thereof. Provided is a method for the in situ derivatization of at least one biogenic amine, precursor or metabolite thereof in an isolated aqueous sample, the derivatization comprising the steps of: (i) contacting said sample with a propionic anhydride/acetonitril solution in the presence of a phosphate buffer having a pH in the range of 7.0 to 9.0 and allowing the conversion of amine and/or hydroxyl moieties of said biogenic amine or metabolite thereof to form a propionyl derivative of said biogenic amine; followed by (ii) adding to the reaction mixture obtained in step (i) a carbodiimide compound and an electrophilic amine-containing compound, and allowing the carbodiimide-mediated derivatization of carboxylic acid moieties of a biogenic amine, precursor or metabolite thereof.

## Claims

### Claim 1

A method for the in situ derivatization of at least one biogenic amine, precursor or metabolite thereof in an aqueous sample, the derivatization comprising the steps of:
(i) contacting said biological sample with a propionic anhydride/acetonitril solution in the presence of a phosphate buffer having a pH in the range of 7.0 to 9.0 and allowing the conversion of amine and/or hydroxyl moieties of said biogenic amine or metabolite thereof to form a propionyl derivative of said biogenic amine; followed by
(ii) adding to the reaction mixture obtained in step (i) a carbodiimide compound and a electrophilic amine-containing compound, and allowing the carbodiimide-mediated derivatization of carboxylic acid moieties of a biogenic amine, precursor or metabolite thereof.

### Claim 2 (depends on 1)

Method according to claim 1, wherein said sample is an isolated aqueous biological sample, preferably wherein the sample is selected from the group consisting of urine, plasma, saliva, CSF, cell lysate and cell culture supernatant.

### Claim 3 (depends on 1, 2)

Method according to claim 1 or 2, wherein said propionic anhydride/acetonitril solution is 10-50% v/v propionic anhydride in acetonitrile.

### Claim 4

Method according to any one of the preceding claims, wherein the pH of said phosphate buffer is in the range of 8.0 to 8.5.

### Claim 5

Method according to any one of the preceding claims, wherein an internal standard is added to the sample.

### Claim 6

Method according to any one of the preceding claims, wherein step (i) comprises mixing 1 volume of (biological) sample, 1 volume of internal standard and 5 volumes of phosphate buffer, and contacting the mixture with 1 volume of propionic anhydride in acetonitrile.

### Claim 7

Method according to any one of the preceding claims, wherein step (ii) comprises adding 2 volumes of the carbodiimide and 2 volumes of the primary amine-containing compound to 1 volume of the reaction mixture obtained in step (i).

### Claim 8

Method according to any one of the preceding claims, wherein step (ii) comprises adding 2,2,2-trifluroethylamine (TFEA) and N-ethyl-N′-(3-dimethylaminopropyl) carbothimide (EDC), preferably 0.4 M TFEA and 0.4 M EDC.

### Claim 9 (depends on 8)

Method according to claim 8, wherein TFEA is added prior to EDC, preferably with vortexing in between.

### Claim 10

Method according to any one of the preceding claims, further comprising, following step (ii), a centrifugation step.

### Claim 11

Method according to any one of the preceding claims, wherein said biogenic amine is selected from the group consisting of L-DOPA, epinephrine, norepinephrine, dopamine, 5-hydroxytryptophan, serotonin, 5-hydroxyindolacetic acid, metanephrine, normetanephrine and 3-methoxytyramine.

### Claim 12

Method according to any one of the preceding claims, further comprising detecting at least one derivatized biogenic amine by subjecting the derivatized sample to (in-line) SPE-LC-MS/MS.

### Claim 13 (depends on 12)

Method according to claim 12, wherein said detecting is performed at least one week after derivatization.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

A kit-of-parts for performing the in situ derivatization method according to any one of claims 1-13, the kit comprising at least
(i) a first container comprising 10-50% v/v propionic anhydride in acetonitrile;
(ii) a second container comprising carbodiimide compound, preferably N-ethyl-N′-(3-dimethylaminopropyl) carbodiimide (EDC) or 1-cyclohexyl-3-(2-morpholinoethyl)carbodiimide (CMC); and
(iii) a third container comprising a primary amine-containing compound, preferably 2,2,2-trifluroethylamine (TFEA).

### Claim 15 (depends on 14)

Kit according to claim 14, further comprising a phosphate buffer having a pH in the range of 7.0 to 9.0 and/or at least one biogenic amine internal standard, preferably selected from the group consisting of L-DOPA-d3, dopamine-d4-HCl, norepinephrine-d6-HCl, serotonin-d4 creatinine sulfate, 5-HIAA-d2, epinephrine-d3, 3-methoxytyramine-d4-HCl, DL-metanephrine-d3-, and DL-normetanephrine-d3-HCl.
